Back to Library

Johnson & Johnson

Clearer skin is possible

Written by
Johnson & Johnson logoJohnson & Johnson
• Published August 8, 2025 • Updated August 8, 2025 Sponsored Content
Clearer skin is possible

IN MODERATE TO SEVERE PLAQUE PsO

PASI resultsIGA results

Patients saw clearer skin at Week 161,2

VOYAGE 1: Major secondary endpoints at Weeks 16, 24, and 48 (NRI)*

PASI Results
PASI Results

The same patients may not have responded at each time point.

VOYAGE co-primary endpoints at Week 16 (NRI)1,2:

VOYAGE 1—PASI 90: TREMFYA® 73% (241/329), placebo 3% (5/174) (P<0.001). IGA 0/1: TREMFYA® 85% (280/329), placebo 7% (12/174) (P<0.001). VOYAGE 2—PASI 90: TREMFYA® 70% (347/496), placebo 2% (6/248) (P<0.001). IGA 0/1: TREMFYA® 84% (417/496), placebo 8% (21/248) (P<0.001).

Psoriasis Symptoms and Signs Diary (Week 16): Greater improvements in symptoms of psoriasis (itch, pain, stinging, burning, and skin tightness).2

VOYAGE 2: Major secondary endpoint at Week 16 (NRI)1,2*†

  • 64% (102/160) of patients receiving TREMFYA® achieved PASI 90 vs 42% (34/81) of patients receiving Humira®

VOYAGE 2: Major secondary endpoint at Week 24 (NRI)1,2*‡

  • 71% (113/160) of patients receiving TREMFYA® achieved PASI 90 vs 51% (41/81) of patients receiving Humira®

*Results from North American sites only, which used US-licensed Humira®.

†P<0.001 vs Humira®.

‡P=0.003 vs Humira®.

Humira is a registered trademark of Abbvie Biotechnology Ltd. Corporation.

NRI=nonresponder imputation.

References: 1. Data on file. Janssen Biotech, Inc. 2. TREMFYA® (guselkumab) [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.

The majority of patients saw clearer skin with TREMFYA®1,2

VOYAGE 1: Major secondary endpoints at Weeks 16, 24, and 48 (NRI)*

PASI Results
PASI Results

The same patients may not have responded at each time point.

VOYAGE co-primary endpoints at Week 16 (NRI)1,2:

VOYAGE 1—PASI 90: TREMFYA® 73% (241/329), placebo 3% (5/174) (P<0.001). IGA 0/1: TREMFYA® 85% (280/329), placebo 7% (12/174) (P<0.001). VOYAGE 2—PASI 90: TREMFYA® 70% (347/496), placebo 2% (6/248) (P<0.001). IGA 0/1: TREMFYA® 84% (417/496), placebo 8% (21/248) (P<0.001).

Psoriasis Symptoms and Signs Diary (Week 16): Greater improvements in symptoms of psoriasis (itch, pain, stinging, burning, and skin tightness).2

VOYAGE 2: Major secondary endpoint at Week 16 (NRI)1,2*‡

  • 74% (119/160) of patients receiving TREMFYA® achieved IGA 0/1 vs 62% (50/81) of patients receiving Humira®

VOYAGE 2: Major secondary endpoint at Week 24 (NRI)1,2*§

  • 74% (119/160) of patients receiving TREMFYA® achieved IGA 0/1 vs 57% (46/81) of patients receiving Humira®

Humira is a registered trademark of Abbvie Biotechnology Ltd. Corporation.

Nonresponder imputation (NRI) methods were used for analysis.

*Results from North American sites only, which used US-licensed Humira®.

†P<0.001 vs Humira®.

‡P<0.027 vs Humira®.

§P=0.005 vs Humira®.

References: 1. Data on file. Janssen Biotech, Inc. 2. TREMFYA® (guselkumab) [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.

Register for Updates

No footer content content fetched

Last updated 04/24

No footer links content fetched